Addex Therapeutics (ADXN) director details 219,561 shares and 50,000 options

Rhea-AI Filing Summary

Addex Therapeutics director Isaac Manke reported his initial holdings. He directly owns 219,561 shares of Common Stock listed on the SIX Swiss Exchange and holds stock options on 50,000 shares of Common Stock with a $0.064 exercise price.

The stock options began vesting in equal monthly installments over a four-year period starting on January 8, 2024 and expire on January 7, 2034. The exercise price is reported in U.S. dollars based on a CHF-to-USD exchange rate as of March 12, 2026.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Manke Isaac

(Last) (First) (Middle)

405 DORADO BEACH EAST

(Street)

DORADO PUERTO RICO 00646

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Addex Therapeutics Ltd. [ ADXN ]

3a. Foreign Trading Symbol
[ADXN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	219,561(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock-option (Right to Buy)	01/08/2024(2)	01/07/2034	Common Stock	50,000	$0.064(3)	D

Explanation of Responses:

1. Represents 219,561 shares of Common Stock listed on SIX Swiss Exchange.

2. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.

3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.2769 per CHF 1.00 as of March 12, 2026.

Remarks:

Exhibit List : Exhibit 24 - Power of Attorney

	/s/ Lenaic Nathanael Teyssedou by power of attorney	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What shareholdings does Isaac Manke report in Addex Therapeutics (ADXN) Form 3?

Isaac Manke reports direct ownership of 219,561 shares of Common Stock in Addex Therapeutics. A footnote states these shares are listed on the SIX Swiss Exchange, establishing his initial equity stake as a director in the company.

What stock options does Isaac Manke hold in Addex Therapeutics (ADXN)?

He holds stock options over 50,000 shares of Addex Therapeutics Common Stock. Each option allows purchase of one ADXN share listed on the SIX Swiss Exchange, providing additional potential equity exposure beyond his directly held common shares.

What is the exercise price and currency basis of Isaac Manke’s Addex (ADXN) options?

The stock options have an exercise price of $0.064 per share. This price is reported in U.S. dollars and reflects conversion from Swiss francs using an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026.

How do Isaac Manke’s Addex (ADXN) stock options vest over time?

The options vest in equal monthly installments over four years, beginning on the exercisable date of January 8, 2024. This schedule gradually increases his exercisable option holdings rather than granting full vesting on a single date.

When do Isaac Manke’s Addex Therapeutics (ADXN) stock options expire?

The reported stock options expire on January 7, 2034. After this expiration date, any unexercised options would lapse, limiting the time window during which he can choose to purchase Addex Therapeutics Common Stock under these option terms.

On which exchange are Isaac Manke’s Addex (ADXN) shares and options referenced?

The 219,561 common shares and each share underlying the stock options are described as listed on the SIX Swiss Exchange. This indicates the primary listing venue referenced for both his current holdings and the potential shares from option exercises.